Pharmacodynamic and Clinical Results from a Phase I/II Study of the HSP90 Inhibitor Onalespib in Combination with Abiraterone Acetate in Prostate Cancer.
Susan SlovinSyed HussainFred SaadJorge GarciaJoel PicusRoberta FerraldeschiMateus CrespoPenelope FlohrRuth RiisnaesChihche LinHarold KeerAram OganesianPaul WorkmanJohann de BonoPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2019)
Onalespib in combination with AA/P showed mild evidence of some biological effect; however, this effect did not translate into clinical activity, hence further exploration of this combination was not justified.